Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029204 · ClinicalTrials.gov registry record · Early Phase 1
Intralesional Cyclosporine for Alopecia Areata
A Early Phase 1 study of Alopecia Areata, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07029204 is a Early Phase 1 study of Alopecia Areata that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 12 participants, below the 1,955-participant average among 26 other Alopecia Areata trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07029204, a Early Phase 1 study of Alopecia Areata, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring, focal areas of hair loss. Due to its resulting disfigurement and unpredictable course, it is recognized as a serious medical condition with severe emotional and psychosocial distress, including a high prevalence of depression and anxiety.1-4 Treatment options for alopecia areata are limited. Cyclosporine has been used as an effective therapeutic option in the treatment of psoriasis. Additionally, the use of oral cyclosporine, alone or in combination with other agents, has been used in the management of a multitude of dermatologic conditions, including alopecia areata, pyoderma gangrenosum, chronic idiopathic purpura, atopic dermatitis, dyshidrotic eczema, Behcet disease, dermatomyositis, among others.8 Although cyclosporine has demonstrated efficacy in the management of these diseases, systemic side effects of oral cyclosporine often limit its long-term use. However, intralesional injections of cyclosporine have not been investigated. Through this randomized double-blind placebo-controlled clinical study, the study team aims to evaluate the safety, dosing, and efficacy of intralesional cyclosporine for use in the treatment of alopecia areata. The study team expects about 12 people at UC Davis to take part in this research. The study itself includes 11 visits and will last about 12 weeks.
Conditions Studied
Interventions
- DRUG CycloSPORINE Injectable Product
- DRUG Saline Solution
Study Locations (1)
California
- University of California, Davis - Dermatology Department - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2026-10-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029204
The ClinicalTrials.gov registry entry for NCT07029204 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,955-participant average among 26 other Alopecia Areata trials with a reported enrollment target (99% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which CycloSPORINE Injectable Product is the first listed.
NCT07029204 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07029204 about?
NCT07029204 is a clinical study titled "Intralesional Cyclosporine for Alopecia Areata". Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring, focal areas of hair loss. Due to its resulting disfigurement and unpredictable course, it is recognized as a serious medical condition with severe emotional and psychosocial distress, including a high prevalence of depres...
What is the current status of trial NCT07029204?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2025-08-19. Estimated completion is 2026-10-01.
What conditions does trial NCT07029204 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT07029204?
The interventions under investigation include: CycloSPORINE Injectable Product (DRUG), Saline Solution (DRUG).
Who is sponsoring clinical trial NCT07029204?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029204 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
RECRUITING
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.